APOE and Mental deterioration: Studies examining the relationship of CR proxy measures and APOE-ε4 carrier status to longitudinal cognitive decline have been most often conducted among individuals across the clinical spectrum (i.e., including combined groups of participants who are cognitively normal and have mild cognitive impairment (MCI) or those with normal cognition, MCI, and dementia).